期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
慢性肝病不同肝纤维化阶段的肝脏体积及其病理变化特点 被引量:1
1
作者 朱亭亭 李正鑫 +5 位作者 袁杰 黄恺 陈高峰 国荣芳 赵志敏 刘成海 《中华肝脏病杂志》 CAS CSCD 北大核心 2024年第6期517-524,共8页
目的:测量不同肝纤维化程度慢性肝病患者的肝脏整体与分叶体积,并观察患者肝脏微血管、肝细胞消亡与再生等病理改变,以期了解肝纤维化时肝脏宏观体积变化及其与肝组织微观病理的联系。方法:收集同时进行肝活检组织和腹部磁共振成像检查... 目的:测量不同肝纤维化程度慢性肝病患者的肝脏整体与分叶体积,并观察患者肝脏微血管、肝细胞消亡与再生等病理改变,以期了解肝纤维化时肝脏宏观体积变化及其与肝组织微观病理的联系。方法:收集同时进行肝活检组织和腹部磁共振成像检查的慢性乙型肝炎、酒精性脂肪肝、自身免疫性肝病、非酒精性脂肪性肝病、药物性肝病的慢性肝病患者53例。采用Masson染色并根据Ishak肝纤维化分期,将患者分为肝纤维化早期(F1~2)、中期(F3~4)和晚期(F5~6)。应用ITK-SNAP软件测量肝脏和脾脏体积。通过CD31免疫组织化学染色反映肝内血管生成,Ki67与肝细胞核因子4α多重荧光免疫组织化学染色反映肝细胞再生,谷氨酰胺合成酶(GS)染色判断肝实质细胞消亡,原位末端标记法观察肝细胞凋亡。Spearman相关性分析肝体积变化与肝组织病理变化之间的关系。结果:随着肝纤维化进展,总肝体积和右肝叶体积逐渐降低(P<0.05),脾脏体积逐渐升高(P<0.05),CD31、GS的表达逐渐增加(P<0.05),Ki67的表达先升高后下降(P<0.05)。CD31阳性率与右肝叶体积(r=-0.609,P<0.001)和总肝体积(r=﹣0.363,P=0.017)呈负相关。Ki67阳性率与右肝叶体积呈正相关(r=0.423,P=0.018),凋亡细胞的阳性率与总肝体积呈显著负相关(r=-0.860,P<0.001)。GS阳性率与右肝叶体积呈负相关(r=﹣0.440,P=0.002),肝细胞消亡数量与右肝叶体积呈负相关(r=﹣0.476,P=0.013)。CD31阳性染色面积与Ki67阳性染色面积呈负相关(r=﹣0.511,P=0.009)。结论:随肝纤维化进展,患者总肝体积与右肝叶体积缩小,主要与肝组织中肝细胞减少与微血管紊乱有关。 展开更多
关键词 纤维化 体积 肝细胞消亡 再生 细胞血管生成 诊断
原文传递
Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells 被引量:30
2
作者 De-JianDai Cai-DeLu +4 位作者 Ri-YongLai Jun-MingGuo HuaMeng Wei-ShengChen JunGu 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第2期193-199,共7页
AIM: To evaluate the effects of survivin on cell proliferation and apoptosis in liver cancer. METHODS: MTT assay was used to generate and optimize phosphorothioate antisense oligonucleotides (ODNs)-LipofectamineTM2000... AIM: To evaluate the effects of survivin on cell proliferation and apoptosis in liver cancer. METHODS: MTT assay was used to generate and optimize phosphorothioate antisense oligonucleotides (ODNs)-LipofectamineTM2000 (LiP) compound by varying ODNs (μg): LiP (μL) ratios from 1:0.5 to 1:5. Then, liver cancer cells (HepG2) were transfected with the compound. By using RT-PCR and Western blot, the expression levels of survivin mRNA and proteins were detected in HepG2 cells treated with antisense compounds (ODNs:LiP=1:4), and compared with those treated with sense compounds (1:4) as control. MTT assay was applied to the determination of cell proliferation in HepG2 cells. Active caspase-3 was evaluated by flow cytometric analysis. The morphological changes were assessed by electron microscopy. Laser scanning confocal microscopy was performed to detect the subcellular localization of survivin proteins in treated and untreated cells. RESULTS: Antisense compounds (1:4) down-regulated survivin expression (mRNA and protein) in a dose-dependent manner with an IC50 of 250 nmol/L. Its maximum effect was achieved at a concentration of 500 nmol/L, at which mRNA and protein levels were down-regulated by 80%. The similar results were found in MTT assay. Antisense compound (l:4)-treated cells revealed increased caspase-3-like protease activity compared with untreated cells. Untreated cells as control were primarily negative for the presence of active-caspase-3. As shown by transmission electron microscopy, treated cells with antisense compounds (1:4) resulted in morphological changes such as blebbing and loss of microvilli, vacuolization in the cytoplasm, condensation of the cytoplasm and nuclei, and fragmented chromatin. Immunofluorescence analysis confirmed the presence of survivin protein pool inside the cytoplasm in untreated cells. Labeled-FITC immunofluorescence staining of survivin clearly showed that survivin was distributed mainly in a spotted form inside the cytoplasm. Whereas cells treated with antisense compounds were rare and weak inside the cytoplasm. CONCLUSION: Down-regulation of survivin expression induced by the antisense compounds reduces tumor growth potential, promotes apoptosis and affects the localization of survivin proteins in HepG2 cells. Furthermore, survivin protein is a key molecule associated with proliferation and apoptosis, and antisense oligonucleotides targeting survivin have a bright prospect in the therapy of liver cancer. 展开更多
关键词 Liver cancer SURVIVIN Cell proliferation Apoptosis
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部